2021-11-15T10:19:23-06:00 2020-12-31 410746749 CLIFTONLARSONALLEN LLP 610 W GERMANTOWN PIKE SUITE 400 PLYMOUTH MEETING PA 19462 990 2020-01-01 460902111 RTOG FOUNDATION INC RTOG 2157170834 50 S 16TH STREET NO 2800 PHILADELPHIA PA 19102 QUYNH-THU LE CHAIRMAN 2157170834 2021-11-12 1 QUYNH-THU LE 999009999 CONNIE M LIRA P00481097 2156433900 2021-11-09 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z QUYNH-THU LE 50 S 16TH STREET NO 2800 PHILADELPHIA PA 19102 7861321 0 X WWW.RTOG.ORG X 2012 PA TO ORGANIZE & PROVIDE FUNDING FOR MULTI-CENTER CLINICAL RESEARCH ACTIVITIES IN ONCOLOGY 10 10 0 11 0 0 4992910 2684323 1961679 5176594 14 2 269 402 6954872 7861321 0 0 0 0 0 0 0 0 0 8588379 8206629 8588379 8206629 -1633507 -345308 2877464 2206431 2079116 1753391 798348 453040 X THE MISSION OF RTOG FOUNDATION, INC. (RTOG) IS TO:(1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS.CONTINUED ON SCHEDULE O 0 0 6703914 0 5176594 RTOG'S PRIMARY PROGRAM CONSISTS OF THE FOLLOWING:(1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS.(2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH.(3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION.(4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY.CONTINUED ON SCHEDULE O(5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION.(6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES.(7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE. 6703914 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 0 0 0 0 PA X THE ORGANIZATION 2157170834 50 S 16TH STREET NO 2800 PHILADELPHIA PA 19102 X WALTER J CURRAN JR MD CHAIR 1.00 X X 0 0 0 MITCHELL MACHTAY MD PRESIDENT 5.00 X X 0 0 0 JAMES DIGNAM MD DIRECTOR 1.00 X 0 0 0 FELIX FENG MD DIRECTOR 1.00 X 0 0 0 LISA KACHNIC DIRECTOR - STARTING 7/13/2020 1.00 X 0 0 0 QUYNH LE MD DIRECTOR 1.00 X 0 0 0 JEFF MICHALSKI MD MBA DIRECTOR 1.00 X 0 0 0 SETH A ROSENTHAL MD DIRECTOR 1.00 X 0 0 0 STUART WONG DIRECTOR - STARTING 7/13/2020 1.00 X 0 0 0 MARIA WERNER-WASIK MD DIRECTOR 1.00 X 0 0 0 HAK CHOY MD DIRECTOR - LEFT JUNE 2020 1.00 X 0 0 0 0 0 0 0 0 0 0 RXCROSSROADS BY MCKESSON 1901 EASTPOINT PKWY LOUISVILLE KY 40223 DISTRIBUTION SERVICE 141148 1 2218250 466073 2684323 CONTRACT REVENUE 900099 5176594 5176594 5176594 2 2 REIMBURSEMENTS 621500 402 402 402 7861321 5176594 0 404 X 22500 22500 851924 390668 461256 10083 8206 1877 2500 2500 63927 22427 41500 17454 17454 4033 4033 RESEARCH PROJECTS 6103989 6103989 SITE EXPENSES 952092 952092 PURCHASES 176124 176124 DUES & SUBSCRIPTIONS 2003 2003 8206629 6703914 1502715 0 694252 1197418 9931 9933 2173281 999080 2877464 2206431 2079116 1753391 2079116 1753391 X 798348 453040 798348 453040 2877464 2206431 -345308 0 X 0 0 0 X 12286004 8011850 7310029 4992910 2684323 35285116 12286004 8011850 7310029 4992910 2684323 35285116 5214826 30070290 3 11 14 2 30 8163 4051 302 269 402 13187 35298333 9473000 0.85190 0.88340 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSEMENTS - 2016 AMOUNT: $ 8,163. 2017 AMOUNT: $ 4,051. 2018 AMOUNT: $ 302. 2019 AMOUNT: $ 269. 2020 AMOUNT: $ 402. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990, PART III, LINE 1 (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH. (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION. (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY. (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION. (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES. (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE THROUGH FELLOWSHIPS AND VARIOUS AWARDS. FORM 990, PART VI, SECTION A, LINE 8B NO BOARD COMMITTEES HAVE BEEN FORMED AS OF THIS TIME. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. THE RETURN WILL THEN BE REVIEWED BY THE SECRETARY-TREASURER AND APPROVED. THE RETURN WILL THEN BE MADE AVAILABLE FOR ALL DIRECTORS PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, STAFF, VOLUNTEERS, CLINICAL INVESTIGATORS AND ALL OTHERS REPRESENTING OR ACTING ON BEHALF OF RTOG. IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST. THE DISCLOSURE IS REVIEWED BY THE RTOG ADMINISTRATOR WITH GUIDANCE FROM RTOG LEGAL COUNSEL. ANY IDENTIFIED FINANCIAL CONFLICT OF INTEREST (FCOI) WILL BE REVIEWED WITH THE AFFECTED INVESTIGATOR AND, IF APPLICABLE, REPORTED TO NIH WITHIN 60 DAYS OF DISCOVERY AND ACTIONS TO MANAGE, REDUCE OR ELIMINATE THE FCOI WILL BE TAKEN BY THE ADMINISTRATOR OF THE RESEARCH ACTIVITY INVOLVED AND INCLUDED IN THE REPORT TO NATIONAL INSTITUTES OF HEALTH (NIH). MANAGEMENT OF AN IDENTIFIED FCOI WILL INCLUDE THE DEVELOPMENT AND IMPLEMENTATION OF A MANAGEMENT PLAN AND, IF NECESSARY, A RETROSPECTIVE REVIEW AND MITIGATION REPORT. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G SUB-AWARD PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 382,428. TOTAL EXPENSES 382,428. STUDY TEAM SERVICES: MANAGEMENT AND GENERAL EXPENSES 287,435. TOTAL EXPENSES 287,435. CONTRACTED RT QA REVIEWS: PROGRAM SERVICE EXPENSES 8,240. TOTAL EXPENSES 8,240. BIOSPECIMEN BANK: MANAGEMENT AND GENERAL EXPENSES 111,321. TOTAL EXPENSES 111,321. OTHER PROFESSIONAL AND CONTRACTED SERVICES: MANAGEMENT AND GENERAL EXPENSES 62,500. TOTAL EXPENSES 62,500.